Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone

BACKGROUND: Abiraterone is a CYP17A1 inhibitor that improves survival in castration-resistant prostate cancer (CRPC). Abiraterone is licensed in combination with prednisone 5 mg twice daily to prevent a syndrome of secondary mineralocorticoid excess. We hypothesised that a ‘steroid switch' from...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorente, D, Omlin, A, Ferraldeschi, R, Pezaro, C, Perez, R, Mateo, J, Altavilla, A, Zafeirou, Z, Tunariu, N, Parker, C, Dearnaley, D, Gillessen, S, de Bono, J, Attard, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264443/
https://www.ncbi.nlm.nih.gov/pubmed/25314055
http://dx.doi.org/10.1038/bjc.2014.531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264443/
https://www.ncbi.nlm.nih.gov/pubmed/25314055
http://dx.doi.org/10.1038/bjc.2014.531

Ejemplares similares